<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017379</url>
  </required_header>
  <id_info>
    <org_study_id>E13018</org_study_id>
    <nct_id>NCT02017379</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.</brief_title>
  <official_title>Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center, El Paso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center, El Paso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study comparing the effect of erythromycin or metoclopramide, 2 prokinetic drugs
      (Drugs which are known to speed up the emptying of the stomach or in other words to move the
      blood out of the stomach faster) given before endoscopy to patients with upper
      Gastrointestinal bleeding compared to patients who will not receive either of these
      medications before their endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy of pre-endoscopic interventions namely erythromycin, metoclopromide
      vs control in improving the outcomes of endoscopy in ICU patients admitted upper GI bleeding.

      Specific aims:

        1. Wither erythromycin, metoclopromide vs control can enable visualization of the entire
           gastric mucosa .

        2. Wither erythromycin, metoclopromide vs control can improve the quality of stomach and
           duodenum visualization: using the scoring system by Fossard et al
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Could not recruit any subjects
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>erythromycin, metoclopromide vs control enabling visualization of the entire gastric mucosa .</measure>
    <time_frame>45 minutes</time_frame>
    <description>Whether erythromycin, metoclopramide versus control can enable visualization of the entire gastric mucosa .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>erythromycin, metoclopromide vs control improving the quality of stomach and duodenum visualization</measure>
    <time_frame>45 minutes</time_frame>
    <description>Whether erythromycin, metoclopramide vs control can improve the quality of stomach and duodenum visualization: using the scoring system by Fossard et al</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Source of bleeding</measure>
    <time_frame>45 minutes</time_frame>
    <description>Ability to identify the source of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second-look endoscopy</measure>
    <time_frame>48 hours</time_frame>
    <description>Need for second-look endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood units transfused</measure>
    <time_frame>48 hours</time_frame>
    <description>Mean number of blood units transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no medications will be given prior to endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <arm_group_label>Erythromycin</arm_group_label>
    <other_name>Erythrocin, E-Mycin, Ery-Tab, Ilosone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopromide</intervention_name>
    <arm_group_label>Metoclopromide</arm_group_label>
    <other_name>Reglan, Maxolon, Metozolv ODT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18-80)

          -  who are admitted to the ICU for hematemesis, or coffee ground emesis

        Exclusion Criteria:

          1. Patients younger than 18 yrs old or older than 80 yrs

          2. Patients who refuse to consent to be in our study

          3. Pregnant patients

          4. Prior use of prokinetics in the last 48 hours

          5. History of cardiac arrhythmia

          6. Allergy to erythromycin or metoclopromide

          7. Patients with QT prolongation (query 7)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed O Othman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University Health Sciences Center, El Paso</investigator_affiliation>
    <investigator_full_name>Mohamed O Othman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>upper gastrointestinal bleeding</keyword>
  <keyword>melena</keyword>
  <keyword>hematemesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

